Adocia Adocia
  • Adocia
    • About
    • History
    • Management
    • Board of directors
    • Advisory board
  • Products and platforms
    • Pipeline
    • Technology Platforms
  • Careers
    • The « Adocians »
    • HR policy
    • Work environment
    • Join us
  • Partnering
  • Investors
  • Media
  • Contact
    • Contact us
    • Map and accessibility
  • Investors
    • Regulated information
    • Stock information
    • Corporate governance
    • General meeting
  • Media
    • Press releases
    • Media
  • EN
    • FR

BioChaperone® Combo, a co-formulation of lispro and glargine, demonstrates both prandial and basal insulin time-action profiles in a single injection in type 2 diabetes, Dr. S. Bruce, 52nd European Association for the Study of Diabetes (EASD) Annual Meeting, 12–16 September 2016, Munich (Germany)

Previous article“BioChaperone® Combo (BC Combo) reduces post-prandial glucose in type 1 diabetes compared to conventional lispro mix 75/25 (LMx)” (Poster 836), presented by Dr. S. Bruce, 52nd European Association for the Study of Diabetes (EASD) Annual Meeting, 12–16 September 2016, Munich (Germany)
Next articleAdocia to hold conference call for investors to provide business update and growth perspectives Wednesday September 21st, 2016 at 6 PM (CET)
Adocia
  • Adocia
  • Products and platforms
  • Careers
  • Partnering
  • Investors
  • Media
  • Contact
Contact us
+33(0)4 72 610 610 contact@adocia.com

Adocia
115 Avenue Lacassagne
69003 Lyon, France

2026 © Adocia

  • Site plan
  • Legal notice
  • Privacy policy and cookies policy
  • Managing cookies
Website by Un Brin de CampagneUn Brin de Campagne